This is a big week for the U.S. dietary supplement sector—on the legal, legislative and regulatory fronts. Consider the following developments...

Due to a complex regulatory structure, the marketing of CBD- and THC-infused beverages is currently controlled by state-specific laws and regulations.

Since more than 70 percent of Americans use supplements, it’s time to explore alternatives to FDA’s regulating the marketplace.

A contested position taken by FDA has raised an important question for the dietary supplement and drug industries, regulators, and potentially, the U.S. courts.

In 6-year-old litigation, the Federal Trade Commission (FTC) last week pushed back against arguments made by Quincy Bioscience that its advertising claims for Prevagen—a brain health supplement—are supported by “competent and reliable scientific...

The regulatory ‘grey zone’ that hemp-derived extracts find themselves in at the federal level could be resolved if Congress decides to act this year.

FDA allows begrudging claim for high blood pressure with magnesium supplements up to 350mg/serving.

Aaron Singerman has faced escalating problems since pleading guilty to federal crimes.

Such de facto pre-market approval of dietary supplements would harm ingredients such as CBD and NAC, while adding nightmarish procedural duties to an agency already missing in action, argues Kyle Turk of NPA.

It’s been nearly a year since FDA announced Steven Tave was leaving his post as director of the Office of Dietary Supplement Programs (ODSP)...